Leonido Luznik, M.D.

Headshot of Leonido Luznik
  • Professor of Oncology
Male

Languages: English, Croatian

Expertise

Bone Marrow Transplant, Graft-versus-Host Disease, Hematologic Malignancies, Medical Oncology ...read more

Research Interests

Graft vs. Host Diseases; Leukemia; Non-Hodgkin's Lymphoma ...read more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Harry and Jeanette Weinberg Building
Baltimore, MD 21231
Phone: 410-502-7732 | Fax: 410-614-1005
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Google Maps

Background

1990-1991 House Officer, University of Zagreb School of Medicine, Zagreb, Croatia
...read more

Titles

  • Professor of Oncology

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD; University Hospital Centre of Zagreb (1990)

Residencies

  • Internal Medicine; University of Arizona College of Medicine (1997)

Fellowships

  • Medical Oncology; Johns Hopkins University School of Medicine (2001)
  • Molecular Biology; University of California San Diego School of Medicine (1994)

Research & Publications

Research Summary

Dr. Luznik's primary research interest is in the area of allogeneic blood and marrow stem cell transplantation (alloBMT). In the laboratory, there are two main areas of ongoing research. The first area focuses on understanding the mechanisms of antitumor immunity after alloBMT. The strategy is to induce immune response against antigens expressed on the tumor (tumor-specific antigens) but not on the normal host hematopoietic and epithelial tissue.

A second area of interest focuses on understanding the critical cellular and molecular mechanisms of acute and chronic GVHD. The long-term goal of these studies is to translate them into the clinic to achieve better antitumor efficacy of alloBMT and to extend the application of this procedure to patients with non-hematopoietic disorders by early induction of tolerance and better prevention of acute and chronic GVHD.

Dr. Luznik's clinical interests are focused on the translation of the concepts developed in the laboratory to early phase clinical trials. He currently leads the multi-institutional clinical trial using high-dose cyclophosphamide as single-agent short course GVHD prophylaxis. (Principal Investigator: L. Luznik; ClinicalTrials.gov Identifier: NCT 00809276). As a part of this clinical trial, his laboratoty is also conducting a systematic study of the correlates of T-cell immune recovery with the goal of identifying critical mechanisms behind the unique ability of high-dose cyclophosphamide to prevent acute and chronic GVHD.

Clinical Trial Keywords

single-agent, short course GVHD prophylaxis; high-dose cyclophosphamide; Lymphoma; Leukemia

Selected Publications





Luznik, L., O’Donnell, P.V., Symons, H.J., Chen, A.R., Leffell, M.S., Zahurak, M., Piantadosi, S., Gooley, T.A., Kaup, M., Ambinder, R.F., Huff, C.A., Matsui, W.H., Bolaños-Meade, J., Borrello, I., Powell, J.D., Flowers, M.,Brodsky, R.A., Sandmaier, B.M., Storb, R.F., Jones, R.J. and E. J. Fuchs: HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-650

Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith, BD, Brodsky R, Huff C, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ.  High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus host disease.  Blood. 2010;115(16):3224-3230

Kanakry, CG., O’Donnell, PV., Furlong, T., de Lima, MJ., Wei, W., Medeot, M., Mielcarek, M., Champlin, RE., Jones, RJ., Thall, PF., Andersson, BS., and L. Luznik: Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. JCO. 2014; 32(31):3497-505

Kanakry CG., Ganguly S., Zahurak M., Bolaños-Meade J., Thoburn C., Perkins B., Fuchs EJ, Jones RJ, Hess AD, L. Luznik: Aldehyde dehydrogenase upregulation drives human regulatory T cell resistance to post-transplantation cyclophosphamide. Sci. Transl. Med. 2013; 5(211)ra157

Kanakry, CG, Fuchs, EJ and L. Luznik: Modern approaches to HLA-haploidenticalblood or marrow transplantation. Nature Rev. Clin. Oncol. 13. 1-14. 2016

Activities & Honors

Memberships

  • American Society of Bone Marrow Transplantation, 1998
  • American Society of Hematology, 1998

Professional Activities

  • Diplomate, Internal Medicine , 1997
  • Diplomate, Hematology, 2001
  • Diplomate, Medical Oncology, 2002
Is this you? Edit Profile
back to top button